Research Progress of Notch Signaling Pathway Related Diseases by Nazir, Hossein & Nahum, Leopold
RESEARCH ARTICLE                               
Genetic Disease Study Volume 2 Issue 1 | 2018 | 1 
Research Progress of Notch Signaling Pathway Related Diseases 
Hossein Nazir, Leopold Nahum 
Genetic Society Group Genetics Collaboration Group, Colombia 
Abstract: Notch signal transduction pathway is one of the important pathways that affect the fate of cells. Adjacent cells 
transmit signals through Notch receptors to regulate the differentiation, proliferation and apoptosis of many kinds of 
cells, including stem cells. Affects organ formation and morphogenesis. Gene mutations of some molecules in Notch 
signaling pathway are related to the occurrence and development of many diseases. On the basis of in-depth study of 
Notch signal transduction pathway, using it as a target to design drugs for the treatment of related diseases, including 
cancer, CADASIL and other hereditary diseases, or the development of stem cell medical techniques. Surgical treatment 
of Alzheimer's disease (disease,AD), Parkinson's disease, diabetes mellitus and other cellular tissue dysfunction or im-
paired diseases has important scientific significance and application value. 
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Notch gene was found in Drosophila in 1919 that a partial deletion of Notch gene caused a notch at the edge of the 
wing of Drosophila melanogaster, hence the name of Notch gene
[1,2]
.Notch signal transduction pathways are widespread 
in vertebrates and non-vertebrates and are highly conserved in evolution. The binding of Notch receptor and ligand 
transmits Notch signal, which enlarges and solidifies the molecular differences between cells, and ultimately determines 
cell fate, affecting organogenesis and morphogenesis. Notch signal changes were also found to be closely related to the 
occurrence and development of many diseases, such as tumours, hereditary diseases, neurodegenerative diseases and 
cardiovascular diseases. Based on the in-depth study of the molecular mechanism of Notch signal and its related dis-
eases, a drug design targeting the Notch signal pathway was carried out to treat Alzheimer's disease and to develop stem 
cell medical technology for the treatment of Alzheimer's disease. Parkinson's disease, diabetes mellitus and other cellu-
lar tissue dysfunction or damaged diseases have important scientific significance and application value. This paper deals 
with the Notch signal Progress in the study of conduction pathways and related diseases is reviewed. 
1. Notch signal transduction pathway 
1.1 Notch receptors and ligands 
Notch receptor is a heterodimer composed of about 300 ku transmembrane,NTM subunits encoded by Notch gene. 
ECN and NTM bind together through non-covalent bonds. The interaction between ECN and NTM is Ca2 dependent
[3]
. 
The extracellular and intracellular domains of Notch receptors are highly conserved. The extracellular domain consists 
of 290.36 epidermal growth factor-like repeat sequences (epidermal growth factor-like re) in the anterior and posterior 
rows of Epidermal growth Factor (EGF). Peats, EGF-R) and three Lin/ Notch repeats (LNR)
[4]
. The existence of Notch 
ligand binding site
[5]
 in the EGF-R domain plays an important role in maintaining the interaction between ECN and 
NTM
[3]
. The short extracellular structure of NTM subunit contains two conserved cysteine residues. Its intracellular 
domain includes RAM (RBP-J kappa associated molecular) domain), There are 7 cdc/ankyrin complex sequence, 2 nu- 
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cleated signal region (NLS) and C terminal PEST junction domain (proline-glutamate- serine-threonine-rich domain)
[4]
. 
PEST is considered to be related to the stability of Notch receptor protein. Notch ligand is also expressed on the cell 
surface of single-transmembrane egg white, adjacent cells through the Notch receptor binding to the ligand transfer 
Notch signal. There are two Notch ligands, Delta and Serrate. in Drosophila. Notch ligand Lag2. in nematode There are 
many kinds of Notch ligands in mammals, and the ligands closely similar to Delta are called Delta single transmem-
brane proteins
[2]
. At present, one Notch gene was found in Drosophila and four Notch genes (Notch1, 2,3C4) were 
found in mammals. Mature Notch acceptor The nucleons are composed of extracellular domains (extracellular 
Notch,ECN) and transmembrane / intracellular domains (Notch or Delta like Delta-like,Dll), similar to Serrate, called 
Serrate or Jagged. Human Notch ligands have been found to have Jagged1,Jagged2,Delta1,Delta3,Delta4
[4]
. The extra-
cellular domain of Notch ligands contains different numbers of EGF like repeats The N-terminal conserved DSL (Delta/ 
Serrate/ Lag2) domain plays a key role in the binding and activation of Notch receptor
[6]
. After the ligand of 
Notch binds to the receptor, the ligand produces receptor-mediated endocytosis. Parks et al.
[7]
 showed that the cytosome 
of the ligand promoted the separation of the receptor heterodimer and the activation of the receptor through the study of 
Drosophila melanogaster. Compared with Notch receptor, the intracellular domain function of Notch ligand is not very 
clear. Recent studies have shown that the intracellular domain of Delta1 can induce cell growth inhibition
[8]
. 
1.2 Notch signaling pathway 
Notch signal transduction pathway is a complex signal sequence composed of a series of molecular events. In the 
whole signaling pathway, Notch gene encodes Notch receptor proteins. It has gone through three shearing processes. 
After ribosomal synthesis, the Notch receptor precursor protein encoded by Notch gene was first cut into two frag-
ments by Fringe glycosyltransferase in Golgi body, and then transferred to cell membrane to form a mature Notch re-
ceptor. When the Notch ligand binds to the recipient, it triggers the activation of the Notch signal and the activation of 
the Notch receptor. For the first time, TNF- α -invertase (TNF- α converting enzyme, TACE) hydrolyzed the Notch re-
ceptor in the extracellular domain to release the extracellular domain, and the second one was the site cleavage protein 
(γ -secretase) / early aging protein (presenilin,PS) near the membrane in the transmembrane region. The intracellular 
domain (intracellular Notch,ICN) was released into the cytoplasm and further transferred to the nucleus
[4,10]. γ -secretase 
is a protein complex composed of PS/NCT/ APH-1/ PEN-2, in which PS contains the active site of γ -secretase[11]. With 
the participation of cofactors such as MAML in the nucleus, the DNA binding protein CSL (CBF in the nucleus is asso-
ciated with its RAM domain and cdc/ankyrin complex sequence. 1/Su (H) / Lag- (-1) conjugates and activates HES 
(hairy/enhancer of split) and other target genes) to activate transcription and play a biological role
[4]
. 
2. Notch signal transduction pathway and disease 
Notch signal transduction pathway exists widely in vertebrates and non-vertebrates and is highly conserved in 
evolution. It plays an important role in embryo, cardiovascular, blood cell development and tumorigenesis. Mutations in 
some molecules or changes in downstream events in the pathway are associated with the occurrence and development 
of many diseases. A disease related to the Notch signaling pathway that has been identified or lurked prior to introduc-
tion. 
2.1 Notch signal transduction pathway and tumor 
In the process of Notch signal regulating cell differentiation, proliferation and apoptosis, the changes of signal 
transduction will lead to tumorigenesis. The relationship between Notch signaling pathway and tumorigenesis has been 
confirmed in T cell leukemia caused by point mutation or chromosome translocation. At present, Notch also occurs in 
pancreatic adenocarcinoma, neuroblastoma (neuroblastoma) and mucoepidermoid carcinoma (mucoepidermoid carci-
noma). Signal change The relationship between Notch signaling pathway and tumorigenesis was first demonstrated in a 
subtype of human acute T lymphocyte leukemia (T-ALL). This subtype was characterized by the translocation of chro-
mosome t (7; 9) (q34; q34.3), which resulted in the incorporation of Notch1 gene into the T cell receptor β (TCR β) 
gene and the formation of an active variant of hNotch1, which eventually led to the over-activation of Notch signal
[12]
. 
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Although t (7) chromosome translocation is only in T-ALL 's In this subtype, however, a further study found that almost 
all T-ALL overexpressed Notch1 or Notch3
[13]
. Recent studies have found that mutations in Notch1 activity are present 
in most T-ALL cases
[14]
. In addition, Notch receptors and ligands were expressed in various tumor cells and tu-
mor-derived cell lines. Animal experiments further confirmed that overexpression of Notch signal would lead to tumor-
igenesis. Compared with small cell lung cancer, Notch1,Notch2 et al. Notch related molecules are highly expressed in 
(NSCLC) of many non-small cell lung cancer and have been used in NSCLC cells for colonization and promotion
[15]
. 
Notch1 and Notch ligand Delta1, Jagged1 were overexpressed in many kinds of Shenjing colloid fine cytoma
[16]
, 
Notch3 was highly expressed in renal cell carcinoma
[17]
, and the transcriptional ICN3 expressed in mice could produce 
T cells. Enhanced expression of Delta4 in Lymphoma
[18]
 The overexpression of Notch1 and Notch3 may induce the 
occurrence of mammary neoplasms in mice
[20]
. The development of these tumors may be related to the continuous pro-
liferation of activated Notch receptors by blocking cell differentiation. Studies have shown that carcinogenic events do 
not necessarily occur at the level of Notch gene expression, but also occur in the lower reaches of the Notch signaling 
pathway. For example, EB virus can produce an egg white substance called EB nuclear antigen 2 (EBNA2), which Egg 
white matter can bind to CSL by mimic ICN, thus activating CSL
[21]
. MAML protein acts as an auxiliary factor in 
the binding of ICN to CSL, while in mucoepidermoid carcinoma, the MAML gene translocation of t (11; 19) (Q14 / 21; 
p12 ~ 13) makes MECT1 gene into MAML2 gene. The fusion product
[22]
, which does not depend on CSL and induces 
Notch target gene epidermis, can induce tumor. In addition, activated N Otch signal can also promote tumor develop-
ment in a wider range by interacting with other signal pathways. Miyamoto et al.
[23]
 found that the activation of Notch 
signal was an early event in human pancreatic neoplasms, and the expression of Notch receptor and ligand was 
up-regulated after activation of RAS/MAPK signal. The results of Brumby et al
[24]
 also showed that Notch could be 
used as a co-oncogene of RAS to promote the development of Drosophila epithelioma. In addition, Notch1, etc. Site 
gene mutants can accelerate the formation and deterioration of lymphoma by synergistic action with Myc
[25]
. Girard et 
al.
[26]
 were also found. After insertion of precancerous toxin into thymoma of MMTVD/myc transgenic mice, the detec-
tion of overexpressed full-length or truncated Notch1, signals suggested that Notch signal might be detected in thy-
moma of MMTVD/myc transgenic mice. Cooperate with c-Myc to promote tumor formation. 
Most of the Notch signals play a carcinogenic role, but in a few cases they inhibit the occurrence and development 
of tumors, which may be related to the different expression levels of related molecules in the microenvironment or 
Notch receptor, ligand and other signal pathways of the cell. This difference ultimately affects cell decisions, leading to 
differences in the fate choices of fine cells in proliferation, cell cycle inhibition, differentiation, self-renewal or apopto-
sis
[27]
. Gramantieri et al.
[28]
 investigate the Notch receptor (Notch1, 2,3,4) in normal and sclerosing human liver tissues 
and liver cancer tissues. To evaluate the relationship between Notch signaling pathway and cell transformation and ma-
lignancy. Compared with normal liver tissue and sclerosing liver tissue, Notch3, 4 was down-regulated in all 20 liver 
cancer samples, and Notch1~4,Delta1 and Jagged1 were down-regulated in 13 of them. The authors suggest that this 
may be related to cell differentiation disorders. 
2.2 Notch signal transduction pathway and hereditary diseases 
The Notch signaling pathway regulates the development of organisms through evolutionarily conserved intercellu-
lar signaling mechanisms. Disrupting the conservative regulatory pathways in the course of development usually leads 
to congenital genetic diseases. Recent studies have shown that Notch signaling regulates the differentiation and 
self-renewal of neural stem cells, hematopoietic stem cells, epidermal stem cells, and so on, in oogenesis, embryonic 
development, myogenesis, neurogenesis, etc. Hematopoiesis and eye development and other processes play an im-
portant role. Gene mutations of related molecules in Notch signal transduction pathway have been demonstrated to be 
associated with CAD ASIL's disease: Alagille syndrome and spinal rib dysplasia. CADASIL disease (cerebral autoso-
mal dominant arteriopathywith subcortical infarcts and leukoencephalopathy), is also called hereditary multiple infarct 
dementia. It is an autosomal dominant cerebral artery disease with subcortical infarction and white matter encephalopa-
thy. The disease is now thought to be due to the smooth muscle of the blood vessel The mutation of the Notch 3 gene 
expressed on the cell was caused by the mutation. Most of the cases were related to the deletion or insertion of cysteine 
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residues in EGF-R (cysteine rich in cysteine) in the extracellular domain of Notch 3. The disulfide bond between the 
cysteine residue pairs in EGF-R ensures that the Notch receptor is folded correctly, and the loss or insertion of the cys-
teine residue leads to the conformation change of Notch 3, which leads to its processing. Defects in the transport pro-
cess affect their interaction with Notch ligands
[29]
. 
Alagille syndrome is an autosomal dominant hereditary disease, which can lead to the absence of various tissues 
and organs, including heart, liver, kidney and so on. It is characterized by normal bile duct deficiency in the liver 
and bile accumulation in the liver caused by extrahepatic bile duct stenosis. The disease is caused by Jagged1 dose defi-
ciency caused by Jagged 1 gene mutation, which is mainly characterized by missense mutation, deletion, truncation and 
splicing of protein, which makes it unable to produce normal Jagged 1 translation product
[30]
. Studies have shown that 
Jagged 1 can down-regulate vascular function. After Jagged 1 gene silencing, the endothelial cells increased the vascu-
lar formation induced by bFGF. The reason for this phenomenon may be that Jagged 1 reduces the responsiveness of 





 proved by location-cloning study that the mutation of the Delta3 gene can lead to autosomal re-
cessive spinal rib dysplasia (spondylocostal dysostosis, SD), which is mainly characterized by the high conserved in-
ternal production of amino acid residues of Delta 3. Missense mutation or production of truncated proteins. 
2.3 Other 
Alzheimer's disease,AD is the main type of Alzheimer's disease. It is a degenerative disease of the central nervous 
system with progressive cognitive impairment and memory impairment as its main clinical manifestation. (senile plaque, 
SP) and neurofibrillar tangles,NFT are the pathological changes. Two of the main features. The main component of the 
old spot is the β -starch egg. β -amyloid protein, A β is produced by the splicing of amyloid precursor protein (amyloid 
precursor protein, APP) by β -secretase and γ -secretase / PS. The main components of NFT are fibrous aggregates 
which are mainly composed of hyperphosphorylated Tau protein. The splicing of APP and Notch receptors is dependent 
on the γ -secretase / PSN Notch signaling pathway. It may be related to the occurrence and development of AD, and the 
change of Notch signal has been found in the research related to AD. Berezovska et al.
[32]
 the expression of Notch1 in 
the hippocampus of sporadic AD patients was more than twice as high as that in the control group. Nagarsheth et al.
[33]
 
showed that the expression of Notch1 in AD was higher than that in the dementia (DLDH) group without characteristic 
histological changes and the control group by immunohistochemistry. meanwhile Compared with DLDH, the abnormal 
aggregation of Tau in AD may be related to AD and other neuropathy caused by Tau aggregates. 
During mammalian development, the formation of organs such as the heart and renal circulation depends on the 
specific vascular system that matches it, which affects the veins. The fate of multiple cells in vascular structures such as 
arteries and capillaries plays a key role in the development and maintenance of the cardiovascular system. The disorder 
of Notch signaling system, which is an important pathway affecting cell decision, is thought to be associated with some 
cardiovascular diseases. Animal model studies have shown that it may affect the cardiovascular system in four ways: 
vascular remodeling, and vascular remodeling. Vascular stability and selective selection of arteriovenous hair (art) Er-
ial-venous specification), heart visceral hair
[34]
. For example, the mutation of Notch1 gene will affect the reconstruction 
of blood vessels in the deep matrix of yolk sac, leading to the collapse of the large motor veins in the dorsal part. The 
mutation of Notch 2 and Jadded 1 gene may cause glomerular capillary plexus defect, right ventricular dysplasia and 
right translocation of aorta
[34]
. The cardiovascular system dysplasia in CADASIL's disease and Alagille's syndrome is 
also caused by Caused by mutations in the Notch 3 or Jagged 1 gene Study on. 
3. Notch signal transduction 
Pathway as a drug target By deeply studying the relationship between the molecular mechanism of disease and the 
Notch signal transduction pathway, using the Notch signal transduction pathway as the drug target, it may be possible to 
achieve the purpose of treating related diseases. In addition, Notch signaling has been proved to be related to the differ-
entiation and proliferation of stem cells such as hematopoietic stem cells and neural stem cells. At present, the study of 
Notch signal transduction pathway as a drug target mainly focuses on the treatment of tumor and expansion of stem 
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cells by inhibiting or activating its signal transduction. 
3.1 Notch signal transduction pathway inhibition and tumor therapy 
Although the Notch signal exhibits tumor inhibition in a few tumors, its signal transduction activation has been 
proved to be related to the occurrence and development of many kinds of tumors. In the treatment of tumors associated 
with Notch, the Notch signal transduction pathway can be used as a viable target for selectively killing tumor cells. In-
hibition of Notch signal by blocking the proliferation of tumor cells. Notch signal can be achieved by blocking lig-
and binding. Recombinant fragments containing more than 2 EGF-R can compete with Notch receptor to bind to Notc 
H ligand to block signal transduction. Rebay et al.
[5]
 proved by large-scale deletion mutagenesis that its second EGF 
repeats 1112 are necessary structures for interaction with Delta in the extracellular domain of Notch acceptor. Notch 
signal could induce the differentiation of 3T3 L1 cells into adipocytes, and the heavy group polypeptide (rh11) contain-
ing the second EGF complex sequence (1112) could significantly inhibit 3T3 L at 10 -7 mol/L. 1 cell differentiation
[35]
. 
In addition, monoclonal antibodies,mAbs can also be used as an inhibitor to block the Notch signaling pathway in 
Notch recipients. It has been proved that rabbit anti rh11-12 mAbs can effectively block the differentiation of 3T3 L1 
cells
[35]
. However, the design of receptor specific blockers is difficult due to the high conserved sequence of several 
Notch receptors. Design of anti-conservative EGF MAbs, in the -R region may be an effective method to block lig-
and binding through steric resistance
[35]
. 
Inhibiting the activity of Fringe,TACE, γ -secretase and other proteases in order to prevent the maturation of Notch 
receptor and the production of ICN could inactivate the Notch signal transduction pathway. For example, melanoma 
cells overexpression of Notch 1 receptor compared with normal proliferative melanocytes, using a small molecule of γ 
-secretase inhibitor-GSI, can block the processing and activation of Notch1~4. Apoptosis of melanoma cells was in-
duced, while normal melanocytes only inhibited G _ 2 / M phase. Inhibiting the activity of ICN directly is also one of 
the effective ways to inhibit Notch signaling pathway. This strategy can inhibit the transcriptional activation of down-
stream genes by inhibiting the formation of CSL-ICN complex or interfering with the binding of other active com-
pounds to CSL-ICN complex. One of the important pathways is that antisense drugs can down-regulate Notch signal-
ing by targeting any part of the signaling pathway. 
In recent years, it has been found that some small molecular compounds can inhibit the Notch pathway to achieve 
the purpose of anti-tumor. Wang et al.
[37]
 showed that genistein inhibited the growth of pancreatic cancer cells and in-
duced apoptosis by inhibiting the activity of Notch 1 and nuclear factor kappaB (NF-kappaB) and their interaction. 
3.2 Notch signal transduction pathway activation and stem cell amplification 
Stem cells are a class of cells with self-renewal (self-renewing) and multi-differentiation potential, which can pro-
duce highly differentiated functional fine cells. Notch signaling plays a decisive role in regulating the directional dif-
ferentiation and self-replication of multipotent stem cells. Stem cell centered regenerative medicine uses normal cells or 
tissues to replace dysfunctional or damaged cellular tissues, using differentiated cells to treat Alzheimer's disease, Park-
inson's disease, and diabetes. Leukaemia and other diseases, Notch signaling pathway by regulating stem cell differenti-
ation and proliferation will be in this Play an important role in a field. In a few cases, such as the differentiation of neu-
ral stem cells into astrocytes, Notch signaling pathway promotes differentiation
[38]
. For many other stem cells, when 
Notch receptors bind to their ligands, dry fine cells proliferate undifferentiated. When the Notch signal activity is inhib-
ited, the stem cells enter the differentiation process and develop into functional cells. The Notch signal transduction 
pathway is considered to be one of the most promising research directions to solve the expansion of stem cells. Cur-
rently Notch The application of signaling pathway in stem cell regenerative medicine is mainly focused on the expan-
sion and culture of stem cells in vitro through activation of Notch signaling pathway. 
Recombinant proteins or peptides from wild Notch ligands are considered effective Notch activators. In vitro ex-
periments have shown that recombinant proteins and peptides derived from Jagged1,Delta1 have Notch activation 
properties. In the process of stem cell culture, activated Notch signaling pathway can regulate the proliferation and dif-
ferentiation of stem cells and serve for stem cell biotherapy and tissue engineering. The strategy is to culture stem / 
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progenitor cells in a medium containing soluble ligands. Or bind the ligands to the solid surface to mimic the ligands in 
vivo. To culture stem / progenitor cells with a cross-membrane structure. Since each type of cell requires a unique cul-
ture condition suitable for it, containing the right amount of cytokines and growth factors, So there are some difficulties 
in maintaining stem cell culture and tissue engineering by activating Notch pathway, although in the culture of hemato-
poietic stem cells, Some progress has been made in maintaining stem cell self-renewal by activating the Notch pathway. 
Human Notch ligand Delta-like 1 (hDll1) was cloned and expressed in
[39]
. The extracellular domain (hDll-1ext) was 
detected by colony culture to amplify the original hematopoietic progenitor cells. Han et al.
[40]
 constructed the soluble 
recombinant protein hDll1NDSL (composed of DSL domain and N-terminal sequence) from human hDll1. It can inhibit 
the differentiation and promote the proliferation of hematopoietic stem cells. 
Gene therapy is another effective way to activate Notch signaling.Genetically engineered cells that lack all or most 
of the extracellular Notch-activated receptors can activate Notch pathways in cell culture and transgenic animals. Acti-
vated Notch can inhibit the differentiation of hematopoietic stem/progenitor cells and promote their proliferation. 
However, because the target gene binds to some viral oncogenic genes, it can be transformed into living cells. There are 
also potential safety risks in receptor gene therapy. 
4. Prospects 
During the development of vertebrates and non-vertebrates, the Notch signal expands and solidifies molecular dif-
ferences between cells, thus playing a key role in determining the fate of cells. Studies have shown that mutations or 
functional deletions in some of its subunits are related to the occurrence and development of many diseases, such as 
tumors, hereditary diseases, Alzheimer's disease and so on. Because of the complexity of Notch signal transduction 
pathway, some molecular mechanisms (such as ligand endocytosis, function of ligand intracellular domain, etc.) are not 
very clear. The molecular mechanism between Notch signal transduction pathway and disease development (No in tu-
mor) is not clear. There is also a need for further elucidation of the tch signal and the cooperated-use machine system of 
c-Mycor Ras and so on. However, there are many potential drug targets in the Notch signal transduction pathway, which 
is based on the further study of the Notch signal transduction pathway and its molecular mechanism with related dis-
eases. Targeting these targets, drugs are designed to block or activate Notch signals, to treat Notch related diseases, or to 
carry out stem cell tissue engineering in the treatment of Alzheimer's disease and diabetes. Parkinson's disease and other 
cellular tissue injury or functional regression diseases have important scientific significance and wide application pro-
spects. 
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